Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex
{{output}}
RAF dimer inhibitors offer therapeutic potential in RAF- and RAS-driven cancers. The utility of such drugs is predicated on their capacity to occupy both RAF protomers in the RAS-RAF signaling complex. Here we describe a method to conditionally quantify drug-t... ...
